NCT05599789 - Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 1, 2023

Primary Completion Date

January 21, 2025

Study Completion Date

December 31, 2025

Conditions

Non Small Cell Lung Cancer Metastatic

Interventions

DRUG

Pembrolizumab in Combination with Plinabulin and Docetaxel

Pembrolizumab 200 mg Q3W IV infusion Day 1 of each 3-week cycle; Plinabulin 30 mg/m2 Q3W IV infusion Days 1 of each 3-week cycle; Docetaxel 75 mg/m² Q3W IV infusion Day 1 of each 3-week cycle.

Trial Locations (1)

100730

Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Beijing